Valneva's Stock Bounces Nearly 2% After a Month Marked by a 15% Decline

A Technical Rebound That Leaves the Stock Below All Its Moving Averages

Valneva's stock gains 1.84% to €2.2730, after a last close at €2.232. The stock is moving slightly away from the support at €2.21 breached last Thursday, as noted in the brief from June 25. The rebound is limited in light of recent dynamics: the stock has lost nearly 15% over one month and 17.7% over three months. The biotech remains below its three main moving averages, with the MM20 at €2.37 (a gap of -4.09%) and the MM50 at €2.44, while the MM200 at €3.64 reflects a deteriorated trajectory over the year (-37.55% gap from the current price). The RSI at 43 remains neutral, with no marked exhaustion signal, suggesting the session is more of a technical breather rather than a trend reversal. The nearest resistance is at €2.67, approximately 17% above the current price. On the index side, the SBF 120 is down 0.09% in the session, in a European market environment lacking clear direction. The stock's rebound places it in the upper half of the index's intraday ranking, but it is not among the most significant movements of the session.

A Biotech Still Penalized by the Reorganization Initiated in Spring

Fundamentally, the stock's trajectory remains marked by the revision of financial ambitions revealed earlier this year. During the first quarter 2026 report (May 13), Valneva adjusted its forecasts and indicated it was targeting revenues between €135 and €150 million for the fiscal year, focusing resources on key strategic projects. The company also cited, among the risks, a decline in third-party product sales and unfavorable trends in travel vaccine adoption. This context continues to weigh on the valuation, with the stock now well below its levels at the beginning of the year. It is worth remembering that the stock is listed on both Euronext Paris and as ADS on Nasdaq since May 2021, with Paris accounting for the bulk of the trading volume. With a decline of more than 37% compared to its 200-day moving average, the value remains distant from its medium-term benchmarks. A sustained crossing of the MM20 at €2.37 would be the first technical signal of stabilization, after several weeks of selling pressure.